MX2021003686A - Medicamento para el tratamiento de la tos cronica. - Google Patents

Medicamento para el tratamiento de la tos cronica.

Info

Publication number
MX2021003686A
MX2021003686A MX2021003686A MX2021003686A MX2021003686A MX 2021003686 A MX2021003686 A MX 2021003686A MX 2021003686 A MX2021003686 A MX 2021003686A MX 2021003686 A MX2021003686 A MX 2021003686A MX 2021003686 A MX2021003686 A MX 2021003686A
Authority
MX
Mexico
Prior art keywords
treating chronic
chronic cough
medicine
pharmaceutical composition
dysgeusia
Prior art date
Application number
MX2021003686A
Other languages
English (en)
Inventor
Erika KASAI
Ryuta TAMANO
Sayaka MIYAZAKI
Katsue MAGARI
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX2021003686A publication Critical patent/MX2021003686A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se proporciona una composición farmacéutica para tratar la tos crónica y que sustancialmente no induce disgeusia como un efecto secundario adverso. Una composición farmacéutica para tratar la tos crónica, que contiene un compuesto representado por la fórmula (I) o una sal farmacéuticamente aceptable del mismo.
MX2021003686A 2018-10-05 2019-10-04 Medicamento para el tratamiento de la tos cronica. MX2021003686A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2018189791 2018-10-05
JP2019044943 2019-03-12
JP2019173841 2019-09-25
PCT/JP2019/039275 WO2020071530A1 (ja) 2018-10-05 2019-10-04 慢性咳嗽治療用医薬

Publications (1)

Publication Number Publication Date
MX2021003686A true MX2021003686A (es) 2021-06-04

Family

ID=70054690

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003686A MX2021003686A (es) 2018-10-05 2019-10-04 Medicamento para el tratamiento de la tos cronica.

Country Status (16)

Country Link
US (1) US11883407B2 (es)
EP (1) EP3862000B1 (es)
JP (2) JP6725188B1 (es)
KR (1) KR102613204B1 (es)
CN (2) CN113164488A (es)
AU (1) AU2019353424B2 (es)
BR (1) BR112021005334A2 (es)
CA (1) CA3115649A1 (es)
ES (1) ES2963702T3 (es)
IL (1) IL282007A (es)
MX (1) MX2021003686A (es)
PH (1) PH12021550713A1 (es)
PL (1) PL3862000T3 (es)
TW (1) TWI804687B (es)
WO (1) WO2020071530A1 (es)
ZA (1) ZA202101756B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114728931A (zh) 2019-09-19 2022-07-08 盐野义制药株式会社 1,3,5-三嗪衍生物或其溶剂合物的晶体及其制造方法
TW202203929A (zh) 2020-04-03 2022-02-01 日商塩野義製藥股份有限公司 疼痛治療用醫藥
WO2021230308A1 (ja) 2020-05-15 2021-11-18 塩野義製薬株式会社 不純物の生成を抑制した医薬組成物
CN113801097B (zh) * 2021-09-27 2022-11-22 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物、其制备方法及用途
CN113773300B (zh) * 2021-09-27 2022-10-11 成都施贝康生物医药科技有限公司 磺酰胺类化合物、其制备方法及用途
CN113620888B (zh) * 2021-09-27 2023-06-06 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773405A4 (en) 2004-07-22 2011-10-05 Duska Scient Co METHOD FOR DIAGNOSIS, MONITORING AND TREATMENT OF LUNG DISEASES
CN1915311A (zh) 2006-08-17 2007-02-21 胡国良 一种治疗顽固性咳嗽的汤剂药物及制备方法
KR101867110B1 (ko) 2010-08-10 2018-06-12 시오노기 앤드 컴파니, 리미티드 트라이아진 유도체 및 그것을 함유하는 진통 작용을 갖는 의약 조성물
CA2898665C (en) 2013-01-31 2021-02-16 Neomed Institute Imidazopyridine compounds and their use as p2x purinoreceptor modulators
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
MX367657B (es) * 2013-08-23 2019-08-30 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.
CN105582039A (zh) 2014-11-10 2016-05-18 刘丰涛 一种治疗干咳痰少的药物
US10174016B2 (en) 2014-12-09 2019-01-08 Beyer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
RS64155B1 (sr) 2015-09-29 2023-05-31 Afferent Pharmaceuticals Inc Diaminopirimidinski modulatori p2x3 i p2x2/3 receptora, za upotrebu u lečenju kašlja
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
KR20210009341A (ko) 2018-05-15 2021-01-26 바이엘 악티엔게젤샤프트 신경 섬유 감작과 연관된 질환의 치료를 위한 1,3-티아졸-2-일 치환된 벤즈아미드

Also Published As

Publication number Publication date
KR20210064273A (ko) 2021-06-02
TW202027751A (zh) 2020-08-01
CN113164488A (zh) 2021-07-23
US20210393640A1 (en) 2021-12-23
AU2019353424A1 (en) 2021-05-06
ES2963702T3 (es) 2024-04-01
JP2021054800A (ja) 2021-04-08
CA3115649A1 (en) 2020-04-09
PL3862000T3 (pl) 2024-03-18
PH12021550713A1 (en) 2021-11-22
AU2019353424B2 (en) 2022-12-08
IL282007A (en) 2021-05-31
JPWO2020071530A1 (ja) 2021-02-15
BR112021005334A2 (pt) 2021-06-15
CN113559104A (zh) 2021-10-29
EP3862000C0 (en) 2023-10-18
JP6725188B1 (ja) 2020-07-15
EP3862000A4 (en) 2022-07-06
US11883407B2 (en) 2024-01-30
WO2020071530A1 (ja) 2020-04-09
TWI804687B (zh) 2023-06-11
EP3862000A1 (en) 2021-08-11
EP3862000B1 (en) 2023-10-18
KR102613204B1 (ko) 2023-12-12
ZA202101756B (en) 2023-06-28

Similar Documents

Publication Publication Date Title
MX2021003686A (es) Medicamento para el tratamiento de la tos cronica.
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
MX2020007485A (es) Compuestos antiproliferativos y metodos de uso de los mismos.
GEP20237568B (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
WO2018086591A8 (zh) 吡啶胺取代的杂三环化合物、其制法与医药上的用途
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
MY197116A (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
TN2017000374A1 (en) TGF-β INHIBITORS
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
MX2021006695A (es) Moduladores de trex1.
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
MX2019006843A (es) Inhibidor de cdk4/6.
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
MX2018014813A (es) Composiciones antibacterianas.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
PH12019550154A1 (en) Azetidine derivative
MY193239A (en) Novel b-lactamase inhibitors
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
AU2015280874A1 (en) Novel heterocyclic compound
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .
EA202091169A1 (ru) Применяемые в качестве ингибиторов iap миметики smac и их применение